bub1 kinase

BAY-1816032 is a benzimidazole budding inhibition relieved homolog protein 1 kinase (BUB1) inhibitor with IC50 of 7 nM and is orally active and abolishes nocodazole-induced Thr-120 phosphorylation of histone H2A, a major BUB1 target protein, in HeLa cells with IC50 of 29 nM.

2OH-BNPP1 is a BUB1 kinase, a Ser/Thr kinase inhibitor, it used for the treatment of cancer.

BAY-524 belongs to small molecule inhibitors and is a Bub1 kinase inhibitor (IC50 = 450 nM under 2 mM ATP conditions) with good cell permeability and selectivity. This compound demonstrates antitumor potential and can be used in research on combination anticancer therapy.

Antitumor agent-180 (Compound 13a) is an inhibitor of BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B). It suppresses the proliferation of ccRCC cells Caki-1 with an IC50 of 2.047 µM and induces necrosis and apoptosis in Caki-1 cells.